Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals' Board of Directors, at its meeting held on December 30, 2025, approved the appointment of Mr. Dinesh Chauhan (DIN: 11456530) as an Additional Non-Executive Independent Director for a period of three years, subject to shareholder approval. The Board also noted the resignation of Ms. Bhoomi Patel (DIN: 08316893) from the position of Independent Director with effect from the same date, citing personal reasons, and confirmed she does not hold directorship in any other listed entity. Following these changes, the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted, with Mr. Dinesh Chauhan appointed as Chairperson of all three committees. Mr. Chauhan brings over 7 years of experience in business management and organizational operations.
This is a routine board reconstitution with one Independent Director stepping down for personal reasons and another appointed in her place, leaving the board composition and committee structure effectively balanced. For shareholders, this is a neutral development with no operational or financial impact, pending shareholder approval for the new appointment.